Hematologic Response of Epoetin Alfa (PROCRIT) Versus Darbepoetin Alfa (ARANESP) in Chemotherapy Induced Anemia
Status:
Completed
Trial end date:
2004-10-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to compare hemoglobin (Hgb) response rates between epoetin alfa
(PROCRIT; 40,000 Units (U) SC weekly) and darbepoetin alfa (ARANESP; 200 mcg every other
week) in anemic cancer patients receiving chemotherapy.